ISRCTN17799325 https://doi.org/10.1186/ISRCTN17799325

Deferred registration: Quotient Sciences Code: QSC302976

Submission date 29/06/2026	**Recruitment status** No longer recruiting	[X] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [X] Record updated in last year
Registration date 03/07/2026	**Overall study status** Deferred	
Last Edited 05/08/2026	**Condition category** Other	

Plain English summary of protocol
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Contact information

Type(s)
Principal investigator

Contact name
Dr David Everton

Contact details
Mere Way, Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)3303031000
recruitment@weneedyou.co.uk

Type(s)
Public, Scientific

Contact name
Dr Robert Faulkner

Contact details
Harmony Biosciences
630 W. Germantown Pike, Suite 215
Plymouth Meeting
United States of America

PA 19462
+1 817-773-1958
rfaulkner@harmonybiosciences.com

Additional identifiers

Integrated Research Application System (IRAS)
1013081

CRO Code
Quotient Sciences Code: QSC302976

Study information

Scientific Title
Deferred registration: Quotient Sciences code: QSC302976 [Full scientific title to be added on or before the deferral expiry date]

Study objectives
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 31/07/2026, South Central - Berkshire Research Ethics Committee (Health Research Authority, 2 Reman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8178; berkshire.rec@hra.nhs.uk), ref: 26/SC/0071

Primary study design
Interventional

Allocation
N/A: single arm study

Masking
Open (masking not used)

Control
Uncontrolled

Assignment
Single

Purpose
Phase I trial in healthy volunteers

Study type(s)

Health condition(s) or problem(s) studied
Healthy volunteers

Interventions
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Primary outcome(s)
1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Key secondary outcome(s)

Completion date
17/09/2026

Eligibility

Key inclusion criteria
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Healthy volunteers allowed
Yes

Age group
Mixed

Lower age limit
30 Years

Upper age limit
65 Years

Sex
Male

Total final enrolment
0

Key exclusion criteria
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Date of first enrolment
11/08/2026

Date of final enrolment
17/09/2026

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Quotient Sciences Limited
Mere Way, Ruddington Fields
Ruddington
Nottingham
England
NG11 6JS

Sponsor information

Organisation
Epygenix Therapeutics, Inc.

Funder(s)

Funder type

Funder Name
Epygenix Therapeutics, Inc.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available